Patients | |||||
---|---|---|---|---|---|
Substance P dose (pmol/min) | Controls | Baseline | Placebo | Pravastatin | |
Data are mean (SEM). *p<0.001, one way analysis of variance in the infused forearm for each group. | |||||
t-PA antigen (ng/ml) | |||||
Infused forearm* | 0 | 5.0 (0.5) | 4.6 (0.8) | 4.7 (0.6) | 4.5 (0.6) |
2 | 5.6 (0.7) | 5.4 (0.8) | 5.4 (0.6) | 5.0 (0.4) | |
4 | 7.4 (0.8) | 5.7 (0.9) | 6.0 (0.9) | 5.8 (0.6) | |
8 | 8.0 (1.3) | 7.4 (1.1) | 7.5 (1.3) | 7.6 (1.1) | |
Non-infused forearm | 0 | 4.7 (0.5) | 4.8 (0.7) | 4.5 (0.6) | 4.6 (0.6) |
2 | 4.6 (0.4) | 4.8 (0.7) | 4.5 (0.5) | 4.5 (0.6) | |
4 | 5.8 (0.6) | 5.1 (0.8) | 4.5 (0.8) | 4.6 (0.6) | |
8 | 5.7 (0.6) | 5.0 (0.8) | 5.1 (0.6) | 4.8 (0.6) | |
t-PA activity (IU/ml) | |||||
Infused forearm* | 0 | 0.6 (0.1) | 0.5 (0.1) | 0.6 (0.1) | 0.5 (0.1) |
2 | 1.7 (0.5) | 1.3 (0.5) | 1.1 (0.4) | 1.6 (0.8) | |
4 | 2.7 (1.0) | 2.0 (0.6) | 1.7 (0.9) | 2.2 (1.1) | |
8 | 4.5 (1.5) | 3.4 (1.1) | 3.9 (1.4) | 3.1 (1.2) | |
Non-infused forearm | 0 | 0.7 (0.1) | 0.4 (0.1) | 0.5 (0.1) | 0.4 (0.1) |
2 | 0.8 (0.1) | 0.5 (0.1) | 0.6 (0.2) | 0.5 (0.1) | |
4 | 1.1 (0.2) | 0.6 (0.1) | 0.7 (0.2) | 0.6 (0.1) | |
8 | 1.7 (0.5) | 0.7 (0.2) | 0.8 (0.2) | 0.7 (0.2) |